# Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%

> **NCT00440141** · PHASE4 · COMPLETED · sponsor: **Allergan** · enrollment: 40 (actual)

## Conditions studied

- Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** latanoprost 0.005% eye drops and brimonidine 0.1% eye drops
- **DRUG:** latanoprost 0.005% eye drops and brinzolamide 1.0% eye drops

## Key facts

- **NCT ID:** NCT00440141
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2007-03
- **Final completion:** 2007-03
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2008-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00440141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00440141, "Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00440141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*